Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarkers of axonal damage to favor early diagnosis in variant transthyretin amyloidosis (A-ATTRv).
González-Moreno J, Gragera-Martínez Á, Rodríguez A, Borrachero-Garro C, García-Garrido S, Barceló C, Manovel-Sánchez A, Ribot-Sansó MA, Ibargüen-González L, Gomila R, Muñoz-Beamud F, Losada-López I, Cisneros-Barroso E. González-Moreno J, et al. Among authors: munoz beamud f. Sci Rep. 2024 Jan 5;14(1):581. doi: 10.1038/s41598-023-50212-2. Sci Rep. 2024. PMID: 38182630 Free PMC article.
A narrative review and expert recommendations on the assessment of the clinical manifestations, follow-up, and management of post-OLT patients with ATTRv amyloidosis.
Casasnovas C, Lladó L, Borrachero C, Pérez-Santamaría PV, Muñoz-Beamud F, Losada-López IA, Baliellas-Comellas MC, González-Moreno J. Casasnovas C, et al. Among authors: munoz beamud f. Ther Adv Neurol Disord. 2023 Aug 24;16:17562864231191590. doi: 10.1177/17562864231191590. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 37655225 Free PMC article. Review.
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay.
Coelho T, Dispenzieri A, Grogan M, Conceição I, Waddington-Cruz M, Kristen AV, Wixner J, Diemberger I, Gonzalez-Moreno J, Maurer MS, Planté-Bordeneuve V, Garcia-Pavia P, Tournev I, Gonzalez-Costello J, Cariou E, González-Duarte A, Glass O, Chapman D, Amass L; THAOS investigators. Coelho T, et al. Amyloid. 2023 Dec;30(4):445-448. doi: 10.1080/13506129.2023.2229484. Epub 2023 Jul 17. Amyloid. 2023. PMID: 37459334 No abstract available.
Follow-up regimens for carriers of hereditary transthyretin variants.
Losada-López IA, Kapetanovic-García S, Sevilla-Mantecón T, Muñoz-Beamud F. Losada-López IA, et al. Among authors: munoz beamud f. Med Clin (Barc). 2023 Mar 10;160(5):213-217. doi: 10.1016/j.medcli.2022.10.002. Epub 2022 Dec 16. Med Clin (Barc). 2023. PMID: 36529555 English, Spanish. No abstract available.
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, Berk JL, González-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L, Chen C, Badri P, Arum SM, Vest J, Polydefkis M; HELIOS-A Collaborators. Adams D, et al. Amyloid. 2023 Mar;30(1):1-9. doi: 10.1080/13506129.2022.2091985. Epub 2022 Jul 23. Amyloid. 2023. PMID: 35875890 Clinical Trial.
Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation.
Schmidt HH, Wixner J, Planté-Bordeneuve V, Muñoz-Beamud F, Lladó L, Gillmore JD, Mazzeo A, Li X, Arum S, Jay PY, Adams D; Patisiran Post-LT Study Group. Schmidt HH, et al. Among authors: munoz beamud f. Am J Transplant. 2022 Jun;22(6):1646-1657. doi: 10.1111/ajt.17009. Epub 2022 Mar 26. Am J Transplant. 2022. PMID: 35213769 Free PMC article. Clinical Trial.
A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.
González-Moreno J, Losada-López I, Cisneros-Barroso E, Garcia-Pavia P, González-Costello J, Muñoz-Beamud F, Campistol JM, Fernandez-Torron R, Chapman D, Amass L. González-Moreno J, et al. Among authors: munoz beamud f. Neurol Ther. 2021 Dec;10(2):833-845. doi: 10.1007/s40120-021-00267-y. Epub 2021 Jul 30. Neurol Ther. 2021. PMID: 34331265 Free PMC article.
Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain.
Galan L, Gonzalez-Moreno J, Martínez-Sesmero JM, Muñoz-Beamud F, Santos-Rubio MD, Tran D, Lebeau P, Stewart M, Mallaina P, Tarilonte P, Peral C, Rozenbaum MH. Galan L, et al. Among authors: munoz beamud f. Expert Rev Pharmacoecon Outcomes Res. 2021 Oct;21(5):967-973. doi: 10.1080/14737167.2021.1900738. Epub 2021 Mar 24. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 33724140 Free article.
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group. Adams D, et al. Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16. Lancet Neurol. 2021. PMID: 33212063 Clinical Trial.
16 results